AstraZeneca PLC (AZN)vsSight Sciences Inc (SGHT)
AZN
AstraZeneca PLC
$195.15
+6.14%
HEALTHCARE · Cap: $284.30B
SGHT
Sight Sciences Inc
$5.45
-3.26%
HEALTHCARE · Cap: $309.59M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 75873% more annual revenue ($60.44B vs $79.55M). AZN leads profitability with a 17.2% profit margin vs -46.8%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
SGHT
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-0.4%
Fair Value
$194.37
Current Price
$195.15
$0.78 premium
Margin of Safety
+30.1%
Fair Value
$7.91
Current Price
$5.45
$2.46 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
No standout strengths identified
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -69.1% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : SGHT
Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : SGHT
The primary concerns for SGHT are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while SGHT is a turnaround play — different risk/reward profiles.
SGHT carries more volatility with a beta of 2.40 — expect wider price swings.
SGHT is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 28/100), backed by strong 17.2% margins and 12.5% revenue growth. SGHT offers better value entry with a 30.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Sight Sciences Inc
HEALTHCARE · MEDICAL DEVICES · USA
Sight Sciences Inc. (SGHT) is a leading medical technology company dedicated to innovating the treatment of ocular diseases, particularly through advanced solutions for glaucoma management. With a strong focus on both surgical and non-surgical methods, the company boasts a diverse product portfolio complemented by a comprehensive intellectual property strategy. As the demand for minimally invasive ophthalmic therapies continues to grow, Sight Sciences is strategically positioned to capture market share and enhance patient outcomes. Its commitment to advancing eye care technology and optimizing its distribution network presents a valuable investment opportunity within the rapidly evolving healthcare landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?